Invesco Ltd. Decreases Position in Illumina, Inc. (NASDAQ:ILMN)

Invesco Ltd. reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 47.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 563,739 shares of the life sciences company’s stock after selling 507,043 shares during the period. Invesco Ltd. owned 0.36% of Illumina worth $75,332,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina during the fourth quarter worth about $32,000. Assetmark Inc. increased its position in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina in the 4th quarter valued at about $48,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Royal Bank of Canada reduced their price objective on Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, April 8th. Citigroup decreased their price target on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Piper Sandler lifted their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Canaccord Genuity Group decreased their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, March 11th. Finally, Morgan Stanley dropped their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.70.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $75.06 on Tuesday. The firm has a market capitalization of $11.89 billion, a price-to-earnings ratio of -9.77, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business’s 50 day simple moving average is $87.59 and its 200-day simple moving average is $121.87. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.